GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...

European Medicines Agency (EMA), in close collaboration with the European Commission, has established a standard procedure ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Teva Pharmaceutical Industries Ltd. ADR-1.51% $18.8B ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

After hours: 7:44:54 p.m. EST ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...